307 related articles for article (PubMed ID: 7913721)
1. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.
Wilson WH; Berg SL; Bryant G; Wittes RE; Bates S; Fojo A; Steinberg SM; Goldspiel BR; Herdt J; O'Shaughnessy J
J Clin Oncol; 1994 Aug; 12(8):1621-9. PubMed ID: 7913721
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results.
Holmes FA; Valero V; Walters RS; Theriault RL; Booser DJ; Gibbs H; Fraschini G; Buzdar AU; Willey J; Frye D; Asmar L; Hortobagyi GN
Ann Oncol; 1999 Apr; 10(4):403-11. PubMed ID: 10370782
[TBL] [Abstract][Full Text] [Related]
3. Update: the M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma.
Holmes FA
Semin Oncol; 1995 Aug; 22(4 Suppl 8):9-15. PubMed ID: 7543702
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer.
Fisherman JS; Cowan KH; Noone M; Denicoff A; Berg S; Poplack D; Balis F; Venzon D; McCabe M; Goldspiel B; Chow C; Ognibene FP; O'Shaughnessy J
J Clin Oncol; 1996 Mar; 14(3):774-82. PubMed ID: 8622023
[TBL] [Abstract][Full Text] [Related]
5. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience.
Buzdar AU; Holmes FA; Hortobagyi GN
Semin Oncol; 1995 Jun; 22(3 Suppl 6):101-4. PubMed ID: 7541151
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.
Seidman AD; Tiersten A; Hudis C; Gollub M; Barrett S; Yao TJ; Lepore J; Gilewski T; Currie V; Crown J
J Clin Oncol; 1995 Oct; 13(10):2575-81. PubMed ID: 7595709
[TBL] [Abstract][Full Text] [Related]
8. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.
Seidman AD; Hochhauser D; Gollub M; Edelman B; Yao TJ; Hudis CA; Francis P; Fennelly D; Gilewski TA; Moynahan ME; Currie V; Baselga J; Tong W; O'Donaghue M; Salvaggio R; Auguste L; Spriggs D; Norton L
J Clin Oncol; 1996 Jun; 14(6):1877-84. PubMed ID: 8656256
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
D'Andrea G; Fennelly D; Norton L; Baselga J; Gilewski T; Hudis C; Moynahan ME; Raptis G; Sklarin N; Surbone A; Theodoulou M; Templeton MA; Yao TJ; Seidman AD
Clin Cancer Res; 1999 Feb; 5(2):275-9. PubMed ID: 10037175
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
Gianni L; Munzone E; Capri G; Fulfaro F; Tarenzi E; Villani F; Spreafico C; Laffranchi A; Caraceni A; Martini C
J Clin Oncol; 1995 Nov; 13(11):2688-99. PubMed ID: 7595726
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel with mitoxantrone with or without 5-fluorouracil and high-dose leucovorin in the treatment of metastatic breast cancer.
Greco FA; Hainsworth JD
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-61-S17-64. PubMed ID: 9374096
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients.
Socinski MA; Mudd PN; Radomski KM; Steagall A; Lawrence P; Bernard S; Letrent SP; Gonzalez P; Brouwer KL
Anticancer Drugs; 1998 Aug; 9(7):611-9. PubMed ID: 9773805
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer.
Schwartsmann G; Mans DR; Menke CH; Xavier N; Caleffi M; Ferreira Filho AF; Schunemann H; Kalakun L; Koya R; Pohlman P; Venegas LF
Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):24-9. PubMed ID: 9144687
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.
Gianni L; Munzone E; Capri G; Villani F; Spreafico C; Tarenzi E; Fulfaro F; Caraceni A; Martini C; Laffranchi A
J Natl Cancer Inst; 1995 Aug; 87(15):1169-75. PubMed ID: 7674322
[TBL] [Abstract][Full Text] [Related]
16. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.
Giordano SH; Booser DJ; Murray JL; Ibrahim NK; Rahman ZU; Valero V; Theriault RL; Rosales MF; Rivera E; Frye D; Ewer M; Ordonez NG; Buzdar AU; Hortobagyi GN
Clin Cancer Res; 2002 Nov; 8(11):3360-8. PubMed ID: 12429622
[TBL] [Abstract][Full Text] [Related]
17. Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer.
Tolcher AW; Cowan KH; Solomon D; Ognibene F; Goldspiel B; Chang R; Noone MH; Denicoff AM; Barnes CS; Gossard MR; Fetsch PA; Berg SL; Balis FM; Venzon DJ; O'Shaughnessy JA
J Clin Oncol; 1996 Apr; 14(4):1173-84. PubMed ID: 8648372
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel and 5-fluorouracil in metastatic breast cancer: the US experience.
Paul DM; Garrett AM; Meshad M; DeVore RD; Porter LL; Johnson DH
Semin Oncol; 1996 Feb; 23(1 Suppl 1):48-52. PubMed ID: 8629038
[TBL] [Abstract][Full Text] [Related]
19. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
[TBL] [Abstract][Full Text] [Related]
20. Dose intensification of mitoxantrone in combination with paclitaxel in advanced breast cancer: a phase II study.
Costanzo FD; Sdrobolini A; Manzione L; Bilancia D; Acito L; Gasperoni S; Valenti L; Fioriti L; Angiona S; Giustini L
Breast Cancer Res Treat; 1999 Mar; 54(2):165-71. PubMed ID: 10424407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
